Global Bioelectronic Medicine Market Outlook, 2031

The global bioelectronic medicine industry covers devices and therapies that use electrical, magnetic or other energy to modulate the nervous system and treat disease, as an alternative or complement to drugs. It includes implantable neuromodulation devices such as spinal cord stimulators for chronic pain, deep brain stimulators for Parkinson's disease, essential tremor and dystonia, vagus nerve stimulators for epilepsy, depression and, since 2025, rheumatoid arthritis, sacral and tibial nerve stimulators for bladder and bowel control, hypoglossal nerve stimulators for obstructive sleep apnoea, baroreflex activation therapy for heart failure, and responsive neurostimulation for epilepsy; non-invasive devices such as transcutaneous nerve stimulators, transcranial magnetic stimulation for depression and non-invasive vagus nerve stimulators for headache; and emerging brain-computer interfaces. The concept of bioelectronic medicine was advanced by research at the Feinstein Institutes, led by Kevin Tracey, showing that the vagus nerve regulates inflammation through the inflammatory reflex. Major companies include Medtronic, Abbott, Boston Scientific, which acquired Axonics in 2024, LivaNova, Nevro, Inspire Medical Systems, NeuroPace, CVRx, electroCore, SetPoint Medical, MicroTransponder, Neuronetics, BrainsWay, Galvani Bioelectronics and Saluda Medical.

Bioelectronic medicine gained major validation in July 2025, when the FDA approved SetPoint Medical's SetPoint System, an implanted vagus nerve stimulator for adults with moderate to severe rheumatoid arthritis who had not responded adequately to biologic or targeted drugs. It was the first bioelectronic device approved to treat an autoimmune disease by activating the body's inflammatory reflex. The approval was based on the RESET-RA sham-controlled trial of 242 patients, the first commercial implant was performed at Northwell Health in August 2025, and CMS granted transitional pass-through payment status from January 2026, supporting reimbursement in hospital outpatient and ambulatory surgery settings. Northwell opened a Center for Bioelectronic Medicine in 2025. Neuromodulation for other conditions has also progressed: Medtronic's adaptive deep brain stimulation for Parkinson's disease, approved in 2025, adjusts stimulation in real time; closed-loop spinal cord stimulators from Medtronic and Saluda sense neural responses; MicroTransponder's Vivistim, approved in 2021, pairs vagus nerve stimulation with rehabilitation to improve arm function after stroke; and Inspire's hypoglossal nerve stimulation has become a major sleep apnoea therapy, although competition from GLP-1 drugs for weight loss has raised questions about demand. Boston Scientific completed its USD 3.7 billion acquisition of Axonics, a maker of sacral neuromodulation devices, in November 2024. Challenges include surgical risk, reimbursement, physician awareness and the need for larger trials in new indications.

Market Dynamics Market Drivers • Need for Alternatives to DrugsMany patients with chronic pain, epilepsy, depression, autoimmune diseases, overactive bladder and sleep apnoea do not respond to or cannot tolerate medications, and concerns about opioids, immunosuppressants and side effects encourage alternatives. Bioelectronic devices offer targeted treatment with fewer systemic side effects, and they can address conditions where drugs have limited effect, supporting adoption among patients and clinicians.
• Advances in Neuroscience and Device TechnologyBetter understanding of neural circuits controlling inflammation, metabolism, pain and organ function has identified new targets, while advances in miniaturisation, closed-loop sensing, wireless power and minimally invasive implantation make devices smaller, safer and more effective. The FDA's approval of the SetPoint System for rheumatoid arthritis validated the concept of treating immune diseases through nerve stimulation.

Market Challenges • Surgical Risk, Cost and ReimbursementImplantable bioelectronic devices require surgery with risks of infection, lead problems and device failure, and they cost tens of thousands of dollars including implantation. Payers may require evidence of long-term benefit and cost-effectiveness, and new indications need specific reimbursement codes and coverage decisions. Some patients prefer drugs or less invasive options, limiting uptake.
• Evidence Requirements and Competition from DrugsDemonstrating efficacy requires sham-controlled trials, which are complex for implanted devices, and responses can vary widely among patients. New drugs can reduce demand for devices, as GLP-1 weight-loss drugs have raised concerns for sleep apnoea devices, and new biologics and oral drugs compete with bioelectronic treatments for autoimmune diseases. Physician awareness of new bioelectronic options remains limited.

Market Trends • Neuroimmune Modulation for Inflammatory DiseasesFollowing the SetPoint approval for rheumatoid arthritis, companies are studying vagus nerve and splenic nerve stimulation for Crohn's disease, multiple sclerosis, lupus and other inflammatory conditions. Research by the Feinstein Institutes, Galvani Bioelectronics and others targets specific nerve fibres to control inflammation. Rheumatologists and gastroenterologists are beginning to consider devices alongside drugs.
• Closed-Loop and Minimally Invasive NeuromodulationNeuromodulation devices increasingly sense biological signals and adjust therapy automatically, including adaptive deep brain stimulation, closed-loop spinal cord stimulation and responsive neurostimulation for epilepsy. Smaller devices implanted through minimally invasive procedures, injectable or wireless stimulators and non-invasive wearable stimulators aim to reduce surgical burden and reach more patients.



Segment Analysis Spinal cord stimulation and deep brain stimulation account for the largest shares of bioelectronic medicine revenue, while vagus nerve stimulation and peripheral nerve stimulation are among the fastest-growing device categories. Spinal cord stimulators, from Medtronic, Abbott, Boston Scientific, Nevro and Saluda, treat chronic back and leg pain, painful diabetic neuropathy and other pain conditions, and they form the largest bioelectronic medicine segment by revenue. Deep brain stimulators treat Parkinson's disease, essential tremor, dystonia and epilepsy, and adaptive closed-loop systems were introduced in 2025. Vagus nerve stimulators, from LivaNova and SetPoint and MicroTransponder, treat epilepsy, treatment-resistant depression, rheumatoid arthritis and stroke rehabilitation, and the rheumatoid arthritis approval opened a large new market. Sacral and tibial nerve stimulators treat overactive bladder, urinary retention and faecal incontinence, with Medtronic and Boston Scientific's Axonics leading. Hypoglossal nerve stimulators from Inspire treat obstructive sleep apnoea. Peripheral nerve stimulators treat localised chronic pain. Responsive neurostimulators treat drug-resistant focal epilepsy. Baroreflex activation therapy from CVRx treats heart failure. Gastric electrical stimulation treats gastroparesis. Non-invasive devices, including transcranial magnetic stimulation for depression, non-invasive vagus nerve stimulation for headache and transcutaneous stimulators for pain, form a large consumer and clinic segment.

Implantable devices account for the largest share of bioelectronic medicine value, while non-invasive devices serve large numbers of patients and are growing in clinic and home use. Implantable bioelectronic devices, including spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, sacral nerve stimulators, hypoglossal nerve stimulators and responsive neurostimulators, generate the largest share of revenue because of high device prices and surgical procedures. Many are rechargeable and programmable, and newer designs are smaller and support MRI scanning. Non-invasive devices, including transcranial magnetic stimulation systems used in psychiatric clinics, transcutaneous electrical nerve stimulation units for pain, non-invasive vagus nerve stimulators for migraine and cluster headache, and wearable neuromodulation devices for migraine and tremor, serve large numbers of patients at lower cost and require no surgery. Minimally invasive and injectable devices, including small wireless stimulators placed through needles, aim to bridge the gap. Brain-computer interfaces, which record and sometimes stimulate neural activity, are an emerging category. Software and programming platforms, including remote programming and apps, are increasingly important parts of bioelectronic therapy.

Chronic pain is the largest application of bioelectronic medicine, while neurological, psychiatric, urological, sleep and inflammatory conditions represent major and growing applications. Chronic pain, including failed back surgery syndrome, chronic back and leg pain, complex regional pain syndrome and painful diabetic neuropathy, is the largest application, treated mainly with spinal cord and peripheral nerve stimulation. Neurological disorders, including Parkinson's disease, essential tremor, dystonia and epilepsy, are treated with deep brain stimulation, vagus nerve stimulation and responsive neurostimulation. Psychiatric disorders, particularly treatment-resistant depression, are treated with transcranial magnetic stimulation, vagus nerve stimulation and, in research, deep brain stimulation, and obsessive-compulsive disorder is also treated with TMS. Urological and bowel disorders, including overactive bladder and faecal incontinence, are treated with sacral and tibial nerve stimulation. Obstructive sleep apnoea is treated with hypoglossal nerve stimulation. Inflammatory and autoimmune diseases became a new application with the SetPoint approval for rheumatoid arthritis. Stroke rehabilitation is supported by paired vagus nerve stimulation. Heart failure and hypertension are treated with baroreflex activation and are areas of research. Headache and migraine are treated with non-invasive devices. Gastrointestinal and metabolic disorders are early research areas.

Hospitals and ambulatory surgery centres are the main settings for implanting bioelectronic devices, while specialty clinics and home care settings manage ongoing therapy. Hospitals perform most complex bioelectronic implants, including deep brain stimulation, responsive neurostimulation and some spinal cord stimulation procedures, and specialised neurosurgery and neurology departments manage these patients. Ambulatory surgery centres increasingly perform spinal cord stimulator, sacral nerve stimulator, hypoglossal nerve stimulator and vagus nerve stimulator implants as outpatient procedures, supported by reimbursement policies such as CMS transitional pass-through payment for the SetPoint System from 2026. Pain management clinics, neurology clinics, urology clinics, sleep centres and, increasingly, rheumatology practices identify candidates, conduct trial stimulation and program devices. Psychiatric clinics provide transcranial magnetic stimulation. Dedicated bioelectronic medicine centres, such as Northwell's, coordinate care across specialties. Home care settings are important because patients use remote controls, chargers and apps to manage devices, and remote programming is growing. Rehabilitation centres use paired stimulation during therapy. Research institutions run trials of new applications.

Regional Analysis North America leads the bioelectronic medicine market because of high adoption of neuromodulation, favourable reimbursement and the concentration of device companies and research institutions, while Europe and Asia-Pacific are significant and growing markets. North America, led by the United States, accounts for the largest share of the bioelectronic medicine market. The United States has high rates of spinal cord stimulation, deep brain stimulation, sacral neuromodulation and hypoglossal nerve stimulation, established reimbursement, and many leading companies, including Medtronic, Abbott, Boston Scientific, Nevro, Inspire, LivaNova's US operations, SetPoint and NeuroPace. The FDA's approval of the SetPoint System for rheumatoid arthritis in July 2025 and CMS's transitional pass-through payment from January 2026, along with approval of adaptive deep brain stimulation in 2025, made the United States the first market for several bioelectronic innovations. Research institutions such as the Feinstein Institutes and Northwell Health lead the field. Canada has growing adoption. Europe is a major market, with strong neuromodulation use in Germany, the UK, France, the Netherlands and Nordic countries, companies such as Onward Medical and Galvani Bioelectronics, and many innovations first approved in Europe under CE marking. Asia-Pacific is the fastest-growing region, as neuromodulation adoption increases in China, Japan, South Korea and Australia, with domestic Chinese device makers producing lower-cost deep brain and vagus nerve stimulators, and Australia home to Saluda Medical. Latin America, the Middle East and Africa have smaller markets focused on major private and academic hospitals.

Key Developments January 2026: CMS granted transitional pass-through payment status for the SetPoint System, providing additional payment for procedures in hospital outpatient and ambulatory surgery settings for up to three years.
August 2025: Northwell Health performed the first commercial implant of the SetPoint System for rheumatoid arthritis, following the opening of its Center for Bioelectronic Medicine.
July 2025: SetPoint Medical's implanted vagus nerve stimulator became the first bioelectronic device approved to treat an autoimmune disease, based on the RESET-RA trial.
2025: Medtronic's BrainSense adaptive DBS became the first closed-loop deep brain stimulation therapy for Parkinson's disease, adjusting stimulation based on brain signals.
November 2024: Boston Scientific completed its USD 3.7 billion acquisition of Axonics, adding sacral neuromodulation devices for bladder and bowel dysfunction.
August 2021: MicroTransponder's Vivistim, which pairs vagus nerve stimulation with rehabilitation, was approved to improve upper limb function in chronic ischaemic stroke patients.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Bioelectronic Medicine Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Device Type
• Spinal Cord Stimulators
• Deep Brain Stimulators
• Vagus Nerve Stimulators
• Sacral and Tibial Nerve Stimulators
• Hypoglossal Nerve Stimulators
• Non-Invasive Stimulation Devices

By Invasiveness
• Implantable Devices
• Minimally Invasive Devices
• Non-Invasive Devices

By Application
• Chronic Pain
• Neurological Disorders
• Psychiatric Disorders
• Urological and Bowel Disorders
• Sleep Apnoea
• Inflammatory and Autoimmune Diseases

By End User
• Hospitals
• Ambulatory Surgery Centres
• Specialty Clinics
• Home Care Settings